Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1998-12-01
2001-01-16
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S450000, C514S643000, C514S654000
Reexamination Certificate
active
06174880
ABSTRACT:
BACKGROUND OF THE INVENTION
Painful fibromuscular disorders are common causes of pain and disability. In particular, fibrositis (also known as fibromyalgia) is a type of fibromuscular disorder that is a frequent cause of debilitating pain arising within muscles or muscle-tendon and tendon-bone junctions. Fibrositis is seen more frequently in women and is characterized by four constant features: pain, stiffness, fatigue and non-restorative sleep. In contrast with most rheumatic disorders, fibrositis rarely is responsive to corticosteroids and non-steroidal anti-inflammatory drugs. The only area in which medications are currently of proven value is in management of the associated sleep disorder.
I have discovered that tricyclic anti-depressants, usually prescribed orally for relief of mental depression or applied topically to the skin to relieve itching in dermatitis as described in my prior U.S. Pat. No. 4,395,420, are surprisingly effective at relieving or moderating the pain, stiffless, fatigue and sleep disorder associated with fibromuscular disorders such as fibrositis when applied topically. These compounds include the pharmaceutically acceptable salts of the tricyclics. The term pharmaceutically acceptable salts, as used herein, refers to the physiologically acceptable acid addition salts such as the hydrochloride, hydrobromide, hydroiodide, acetate, valerate, oleate, etc. Doxepin, amitriptyline and imipramine respectively are the tertiary amine derivatives of dibenzoxepin, dibenzoycloheptadiene and dibenzazepine wherein the nitrogen atom is connected to the ring structure by a three carbon aliphatic chain and the tertiary amine has two carbon atoms attached thereto in addition to the aliphatic chain.
The present invention relates to a method for topically treating fibromuscular disorders such as fibrositis. The principal object of the present invention is to apply topically divided doses of tricyclic anti-depressant compounds traditionally employed systematically for treatment of mental depression to relieve pain, stiffness, fatigue and sleep disorders characteristic of fibrositis. It is speculated that alleviation of the associated sleep disorder may arise either from relief of the pain and stiffness that prevented restful sleep, and/or from the sedative effect that these compounds are known to provide when administered systemically.
This and other objects of the present invention may be more readily understood when considered in conjunction with the following detailed description and examples.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
I investigated the possible therapeutic effects of topically applied formulations of tricyclic anti-depressant compounds in fibrositis by having patients suffering from fibrositis apply doxepin hydrochloride to localized areas of pain and/or stiffness. Patients noted not orgy relief of pain and stiffness as a consequent of such method of treatment, but also reported less fatigue and difficulty sleeping.
In the practice of the invention, concentrations of salts of doxepin, amitriptyline and impramine varying from about 1% by weight to about 10% by weight will be incorporated into creams, ointments, lotions and solutions and applied to patients suffering from fibromuscular disorders in divided doses for the relief of the pain, stiffness, and/or fatigue associated with such disorders. The preferred amount of active ingredients will be from about 1% to about 5% by weight of the carrier.
The following examples further illustrate the invention. In these examples, all percentages are by weight of the carrier.
REFERENCES:
patent: 4395420 (1983-07-01), Bernstein
patent: WO 9710815 (1997-03-01), None
Textbook of Pain,Wall, Patrick D. et al., Third Edition, (1994), pp. 476-480.
Textbook of Rheumatology,Kelley, William N., M.D. et al., (1989), pp. 541-553.
Treatment of Painful Diabetic Neuropathy With Topical Capsaicin,Arch. Intern. Med.,vol. 151, Nov. 1991, pp. 2225-2229.
“A Randomized Vehicle-Controlled Trial of Topical Capsaicin in the Treatment of Postherpic Neuralgia,” Watson et al.,Clinical Therapeutics,vol. 15, No. 3, 1992, pp. 510-526.
“Treatment of Arthritis with Topical Capsaicin: A Double-Blind Trial,” Deal et al.,Clinical Therapeutics,vol. 13, No. 3, 1991, pp. 383-395.
Cook Rebecca
Jones Day Reavis & Pogue
Winston Laboratories, Inc.
LandOfFree
Method for treatment of painful fibromuscular disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of painful fibromuscular disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of painful fibromuscular disorder will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2552055